抗Bcl2相关髓细胞白血病序列1(MCL1)多克隆抗体
Anti-Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) Polyclonal Antibody
EAT; MCL1L; MCL1S; BCL2L3; TM; Myeloid Cell Leukemia Sequence 1, Bcl2 Related; Bcl-2-like protein 3; Bcl-2-related protein EAT/mcl1; mcl1/EAT
- 编号FAC615Hu01
- 物种Homo sapiens (Human，人)相同的名称，不同的物种。
- 效价-
- Ig类型IgG
- 纯化方式抗原特异性亲和纯化
- 标记物无标记物
- 激发波长-
- 单次使用量1-5 µl
- 缓冲液成份0.01M 磷酸盐缓冲液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性状液体
- 且适物种-
- 应用FCM
- 下载英文说明书 中文说明书
- 规格25test50test100test200test500test
- 价格¥ 792¥ 1320¥ 2112¥ 2640¥ 4620
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
产品包装(模拟)
产品包装(模拟)
Human Raji cell line was fixed with 2% paraformaldehyde (10 min) , permeabilised with 0.1% BSA-Triton X-100,then stained with 20µg/ml rabbit Anti-human MCL1 Polyclonal Antibody (Catalog FAC615Hu01, red histogram) or Isotype control antibody (Catalog IS067-Rb01, green histogram), followed by 1µg/ml FITC-conjugated Anti-rabbit IgG Secondary Antibody (Catalog SAA544Rb18).
通过ISO 9001、ISO 13485质量体系认证
用法
For flow cytometry, the suggested use of this reagent is 1-5 µl per 10^6 cells in 100 µl volume.
Optimal working dilutions could be determined by end user.
储存
经常使用则4°C保存。-20°C保存不超过一年。避免反复冻融。
赠品
增值服务
相关产品
| 编号 | 适用物种：Homo sapiens (Human，人) | 应用(仅供研究使用，不用于临床诊断！) |
| RPC615Hu01 | Bcl2相关髓细胞白血病序列1(MCL1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC615Hu01 | Bcl2相关髓细胞白血病序列1(MCL1)多克隆抗体 | WB; FCM |
| FAC615Hu01 | 抗Bcl2相关髓细胞白血病序列1(MCL1)多克隆抗体 | FCM |
| MAC615Hu22 | Bcl2相关髓细胞白血病序列1(MCL1)单克隆抗体 | WB; IHC; ICC; IP. |
| SEC615Hu | Bcl2相关髓细胞白血病序列1(MCL1)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMC615Hu | Bcl2相关髓细胞白血病序列1(MCL1)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
| 杂志 | 参考文献 |
| Cancers | Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia[Pubmed: 31718075] |
| ACTA NEUROPATHOLOGICA COMMUNICATIONS | Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma[Pubmed: 32410663] |
| Cancers (Basel) | BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581[33540760] |